Wooding Hayley, Yan Jing, Yuan Ling, Chyou Te-Yu, Gao Shanbao, Ward Iain, Herst Patries M
1 Canterbury Regional Cancer and Haematology Service, Christchurch Hospital , Christchurch , New Zealand.
2 Comprehensive Cancer Centre, Drum Tower Hospital/Clinical Cancer Institute of Nanjing University , Nanjing , PR China.
Br J Radiol. 2018 Jan;91(1081):20170298. doi: 10.1259/bjr.20170298. Epub 2017 Nov 8.
Mepitel Film significantly decreases acute radiation-induced skin reactions in breast cancer patients. Here we investigated the feasibility of using Mepitel Film in head and neck cancer patients (ACTRN12614000932662).
Out of a total of 36 head and neck cancer patients from New Zealand (NZ) (n = 24) and China (n = 12) recruited between June 2015 and December 2016, 33 patients complied with protocol. Of these, 11 NZ patients followed a management protocol; 11 NZ patients and 11 Chinese patients followed a prophylactic protocol. An area of the neck receiving a homogenous radiation dose of > 35 Gy was divided into two equal halves; one half was randomized to Film and the other to either Sorbolene cream (NZ) or Biafine cream (China). Skin reaction severity was measured by Radiation Induced Skin Reaction Assessment Scale and expanded Radiation Therapy Oncology Group toxicity criteria. Skin dose was measured by thermoluminescent dosimeters or gafchromic film.
Film decreased overall skin reaction severity (combined Radiation Induced Skin Reaction Assessment Scale score) by 29% and moist desquamation rates by 37% in the Chinese cohort and by 27 and 28%, respectively in the NZ cohort. Mepitel Film did not affect head movements but did not adhere well to the skin, particularly in males with heavy beard stubble, and caused itchiness, particularly in Chinese patients.
Mepitel Film reduced acute radiation-induced skin reactions in our head and neck cancer patients, particularly in patients without heavy stubble. Advances in knowledge: This is the first study to confirm the feasibility of using Mepitel Film in head and neck cancer patients.
美皮贴薄膜可显著降低乳腺癌患者急性放射性皮肤反应。在此,我们研究了在头颈部癌患者中使用美皮贴薄膜的可行性(澳大利亚和新西兰临床试验注册号:12614000932662)。
2015年6月至2016年12月期间,共招募了36名头颈部癌患者,其中来自新西兰(n = 24)和中国(n = 12)。33名患者符合方案要求。其中,11名新西兰患者遵循一种处理方案;11名新西兰患者和11名中国患者遵循预防性方案。将接受大于35 Gy均匀辐射剂量的颈部区域分成两个相等的部分;一半随机分配使用美皮贴薄膜,另一半随机分配使用索博来恩乳膏(新西兰)或比亚芬乳膏(中国)。通过放射性皮肤反应评估量表和扩展的放射肿瘤学组毒性标准来测量皮肤反应严重程度。通过热释光剂量计或辐射变色薄膜测量皮肤剂量。
在中国队列中,美皮贴薄膜使总体皮肤反应严重程度(放射性皮肤反应评估量表综合评分)降低了29%,湿性脱屑率降低了37%;在新西兰队列中,分别降低了27%和28%。美皮贴薄膜不影响头部活动,但与皮肤的贴合性不佳,尤其是在胡茬较重的男性中,并且会引起瘙痒,尤其是在中国患者中。
美皮贴薄膜可减轻我们研究中的头颈部癌患者的急性放射性皮肤反应,尤其是在没有浓密胡茬的患者中。知识进展:这是第一项证实美皮贴薄膜在头颈部癌患者中使用可行性的研究。